Targeted Therapies for Migraine Prevention in the Challenging Migraineur: Focus on CGRP Blockade

Review expert-led discussion on emerging and established strategies for migraine prophylaxis with the downloadable slides and on-demand Webcast from CCO’s dynamic symposium at the 2020 Diamond Headache Clinic.
Wade Cooper, DO
Merle Diamond, MD

Downloadable Slideset

Review expert insights into the latest efficacy and safety data on established and investigational CGRP-targeting agents, including monoclonal antibodies, gepants, ditans, and triptans.

Wade Cooper, DO Merle Diamond, MD Released: February 14, 2020

On-Demand Webcast

In this dynamic CME-certified video from a live symposium, expert faculty discuss the clinical application of CGRP-targeting agents in migraine prophylaxis.

Wade Cooper, DO Merle Diamond, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: March 10, 2020 Expired: March 9, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?